AN2 Therapeutics director gifts 405,880 shares

AN2 Therapeutics director Joseph S. Zakrzewski reported a bona fide gift of 405,880 shares of common stock.

Rhea-AI Filing Summary

AN2 Therapeutics director Joseph S. Zakrzewski reported a bona fide gift of 405,880 shares of common stock. The gifted shares were held indirectly through the Z3 Trust, and he disavows beneficial ownership of those shares. Following this transaction, he reports 145,538 shares of AN2 Therapeutics common stock held directly.

Insider Trade Summary

405,880 shares gifted

Gift 2 txns

Insider Zakrzewski Joseph S

Role Director

Type	Security	Shares	Price	Value
Gift	Common Stock F1, F2	405,880	$0.00	$0.00
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 0 shares (Indirect, See footnote); Common Stock — 145,538 shares (Direct)

Footnotes (2)

1. F1. Reflects a gift of shares to the children of the Reporting Person.
2. F2. The shares are held by Nancy Zakrzewski TTEE Z3 Trust U/A DTD 11/25/14 ("Z3 Trust"). The Reporting Person disavows beneficial ownership of the shares held by Z3 Trust.

Key Figures

Shares gifted: 405,880 shares Gift price per share: $0.0000 Indirect shares after gift: 0 shares +2 more

5 metrics

Shares gifted 405,880 shares Bona fide gift of common stock to the children of the reporting person

Gift price per share $0.0000 Reported transaction price per share for the gifted common stock

Indirect shares after gift 0 shares Total indirect holdings following the gift from Z3 Trust

Direct shares after transaction 145,538 shares Directly held AN2 Therapeutics common stock after the reported transactions

Gift transactions count 1 Number of bona fide gift transactions reported in this Form 4

Key Terms

bona fide gift, beneficial ownership, indirect ownership, Rule 10b5-1

4 terms

bona fide gift financial

"Transaction code G is described as a bona fide gift"

A bona fide gift is a genuine, voluntary transfer of money, property, or benefits from one party to another made without expectation of repayment, services, or hidden conditions. Investors care because such gifts can affect company disclosures, related‑party transaction rules, tax treatment, and perceived conflicts of interest; think of it like someone giving you a present with no strings attached — but on a corporate scale, auditors and regulators need to verify it really is unconditional.

beneficial ownership financial

"The Reporting Person disavows beneficial ownership of the shares held"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

indirect ownership financial

"The shares are held by Z3 Trust and reported as indirect ownership"

Rule 10b5-1 regulatory

"A document-level Rule 10b5-1 checkbox is provided but not checked"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AN2 Therapeutics (ANTX) director Joseph S. Zakrzewski report?

Joseph S. Zakrzewski reported a bona fide gift of 405,880 shares of AN2 Therapeutics common stock. The shares were transferred as a gift and not sold for cash consideration, according to the disclosure.

How many AN2 Therapeutics (ANTX) shares were gifted in this Form 4 filing?

The filing reports a gift of 405,880 shares of AN2 Therapeutics common stock. These shares were previously held indirectly through the Z3 Trust before being gifted, as described in the accompanying footnotes.

Who received the gifted AN2 Therapeutics (ANTX) shares from this Form 4 transaction?

The filing states the transaction reflects a gift of shares to the children of the Reporting Person. This means the 405,880 AN2 Therapeutics shares were transferred as a gift to his children.

What are Joseph S. Zakrzewski’s AN2 Therapeutics (ANTX) holdings after the reported gift?

After the reported gift, he reports 145,538 shares of AN2 Therapeutics common stock held directly. The indirect position tied to the Z3 Trust is reported as 0 shares following the gift transaction.

Did Joseph S. Zakrzewski use a Rule 10b5-1 trading plan for this AN2 Therapeutics (ANTX) transaction?

The filing’s Rule 10b5-1 checkbox is not checked, and there is no footnote indicating use of a trading plan. The gift of 405,880 shares is therefore not described as made under a 10b5-1 plan.

Does Joseph S. Zakrzewski claim beneficial ownership of the AN2 Therapeutics (ANTX) shares held by the Z3 Trust?

No. The filing states he disavows beneficial ownership of shares held by the Z3 Trust. Those 405,880 shares were held by the trust and then gifted to his children, per the footnotes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/14/2026 - 02:12 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zakrzewski Joseph S

(Last) (First) (Middle)

C/O AN2 THERAPEUTICS, INC.

1300 EL CAMINO REAL, SUITE 100

(Street)

MENLO PARK CALIFORNIA 94025

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AN2 Therapeutics, Inc. [ ANTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/14/2026		G(1)		405,880	D	$0	0	I	See footnote(2)
Common Stock								145,538	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects a gift of shares to the children of the Reporting Person.

2. The shares are held by Nancy Zakrzewski TTEE Z3 Trust U/A DTD 11/25/14 ("Z3 Trust"). The Reporting Person disavows beneficial ownership of the shares held by Z3 Trust.

	/s/ Lucy Day, Attorney-in-Fact for Joseph S. Zakrzewski	08/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)